Edesa Biotech (EDSA) CEO Pardeep Nijhawan Receives Award

What Happened

• Pardeep Nijhawan, CEO of Edesa Biotech (EDSA), was granted and acquired 5,714 shares via a restricted share unit award on 2026-09-01. The shares were reported as acquired at $0.00 (i.e., no cash paid) and vested in full upon grant under the company's 2019 Equity Incentive Compensation Plan.

Key Details

• Transaction date: 2026-09-01; Transaction type: Award/Grant (code A).
• Shares acquired: 5,714; Reported acquisition price: $0.00; Reported total cash value in filing: $0.
• Footnote F1: These were restricted share units that vested in full upon grant under the 2019 Equity Incentive Compensation Plan.
• Footnotes F2 & F3: Certain shares are held by entities and a family trust wholly owned or co-trusteed by the reporting person; Nijhawan disclaims beneficial ownership of those securities except to the extent of pecuniary interest.
• Shares owned after the transaction: not specified in the information provided in this filing.
• Filing date: 2026-09-01 (same day as the reported transaction), indicating timely reporting.

Context

• This was an award/vesting event (not an open-market purchase or sale). Such grants are typically part of compensation and do not by themselves indicate a buy/sell sentiment. The RSUs vested immediately upon grant, meaning the recipient received the shares without a future vesting schedule.